CLAIMS

1. Use of a hydrophobic composition comprising a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and a plurality of drug nanoparticles,

wherein the mean particle size (number) of the drug nanoparticles is from 0.1 microns to 1.5 microns,

wherein the composition does not contain $C_1 - C_5$ aliphatic alcohols, and

wherein drug nanoparticles are taxane nanoparticles in the preparation of a medicament for use in enhancing penetration of drug nanoparticles into skin to treat a skin condition or disease.

2. The use of claim 1, wherein the volatile silicone fluid is cyclomethicone.

3. The use of claim 2, wherein the cyclomethicone is cyclopentasiloxane.

4. The use of any one of claims 1 to 3, wherein the hydrophobic carrier comprises a hydrocarbon.

5. The use of claim 4, wherein the hydrocarbon is petrolatum, mineral oil, or paraffin wax, or mixtures thereof.

6. The use of any one of claims 1 to 5, wherein the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.

7. The use of claim 6, wherein the taxane nanoparticles are paclitaxel nanoparticles.

8. The use of claim 7, wherein the paclitaxel nanoparticles have a specific surface area (SSA) of at least 18 m^2/g.

9. The use of any one of claims 1 to 8, wherein the composition is a semi-solid composition.

10. The use of claim 9, wherein the semi-solid composition is an ointment.

11. The use of claim 9 or claim 10, wherein the viscosity of the composition is 25,000 cps to 500,000 cps as measured with a Brookfield RV viscometer on a helipath stand with the helipath on, with a T-E spindle at 10 RPM at room temperature for 45 seconds.

12. The use of claim 11, wherein the taxane nanoparticles are at a concentration of 0.1 to 5% w/w.

13. The use of claim 1, wherein the hydrophobic composition consists essentially of the continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and the plurality of drug nanoparticles,

wherein the volatile silicone fluid is cyclopentasiloxane,

wherein the continuous hydrophobic carrier is non-volatile and non-polar, greater than 50% w/w of the composition, and consists essentially of petrolatum, heavy mineral oil, and paraffin wax, and

wherein the composition is an anhydrous semi-solid ointment.

14. The use of claim 13, wherein:

other than cyclopentasiloxane, the hydrophobic composition does not contain an additional skin penetration enhancer nor an additional volatile solvent; and

the hydrophobic composition does not contain a surfactant.

15. The use of claim 13, wherein the drug nanoparticles are paclitaxel nanoparticles, wherein the paclitaxel nanoparticles are at a concentration of 0.1 to about 5% w/w, and wherein the composition does not contain a protein or albumin.

16. The use of any one of claims 1-15, wherein the skin condition or disease is psoriasis.

17. A hydrophobic composition comprising a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and a plurality of drug nanoparticles,

wherein the mean particle size (number) of the drug nanoparticles is from 0.1 microns to 1.5 microns,

wherein the composition does not contain $C_1 - C_5$ aliphatic alcohols, and

wherein the drug nanoparticles are taxane nanoparticles.

18. The composition of claim 17, wherein the volatile silicone fluid is cyclomethicone.

19. The composition of claim 18, wherein the cyclomethicone is cyclopentasiloxane.

20. The composition of any one of claims 17 to 19, wherein the hydrophobic carrier comprises a hydrocarbon.

21. The composition of claim 20, wherein the hydrocarbon is petrolatum, mineral oil, or paraffin wax; or mixtures thereof.

22. The composition of any one of claims 17 to 21, wherein the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.

23. The composition of claim 17, wherein the taxane nanoparticles are paclitaxel nanoparticles.

24. The composition of claim 23, wherein the paclitaxel nanoparticles have a specific surface area (SSA) of at least 18 m^2/g.

25. The composition of any one of claims 17 to 24, wherein the composition is a semi-solid composition.

26. The composition of claim 25, wherein the semi-solid composition is an ointment.

27. The composition of claims 25 or claim 26, wherein the viscosity of the composition is 25,000 cps to 500,000 cps as measured with a Brookfield RV viscometer on a helipath stand with the helipath on, with a T-E spindle at 10 RPM at room temperature for 45 seconds.

28. The hydrophobic composition of claim 17 consisting essentially of the continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and the plurality of drug nanoparticles,

wherein the volatile silicone fluid is cyclopentasiloxane,

wherein the continuous hydrophobic carrier is non-volatile and non-polar, greater than 50% w/w of the composition, and consists essentially of petrolatum, heavy mineral oil, and paraffin wax, and

wherein the composition is an anhydrous semi-solid ointment.

29. The hydrophobic composition of claim 28, wherein:

other than cyclopentasiloxane, the hydrophobic composition does not contain an additional skin penetration enhancer nor an additional volatile solvent; and

the hydrophobic composition does not contain a surfactant.

30. The composition of claim 28, wherein the drug nanoparticles are paclitaxel nanoparticles, wherein the paclitaxel nanoparticles are at a concentration of 0.1 to about 5% w/w, and wherein the composition does not contain a protein or albumin.

31. The composition of claim 17, wherein the taxane nanoparticles are at a concentration of 0.1 to 5% w/w.